NCT00506545View on ClinicalTrials.gov

Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Cough
Interventions
DRUG

SCH 619734

SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.

DRUG

Placebo Dose 1

Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00506545 - Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888) | Biotech Hunter | Biotech Hunter